Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 May;26(5):251-6.
doi: 10.1007/s10815-009-9326-6. Epub 2009 Jul 23.

Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial

A Sismanoglu  1 , H I Tekin, H F Erden, N H Ciray, U Ulug, M Bahceci
Affiliations
Clinical Trial

Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial

A Sismanoglu et al. J Assist Reprod Genet. 2009 May.

Abstract

Objective: To compare fertilization, implantation and pregnancy rates in donor oocyte cycles triggered for final oocyte maturation with either human chorionic gonadotropin (hCG) or gonadotropin releasing hormone (GnRH) agonist in the same donor population in two sequential stimulation cycles.

Design: Prospective randomized cross-over trial.

Setting: Private infertility clinic.

Patient(s): Eighty-eight stimulation cycles in 44 egg donors.

Interventions: Controlled ovarian hyperstimulation (COH) with GnRH antagonist protocol triggered with hCG or GnRH agonist (leuprolide acetate 0.15 mg) in the same egg donors in two consecutive cycles.

Main outcome measure(s): The primary outcome measure was the proportion of mature and fertilized oocytes per donor cycle. Secondary outcome measures were implantation and pregnancy rates in the recipients and incidence of ovarian hyperstimulation syndrome (OHSS) in oocyte donors.

Result(s): The proportion of mature oocytes, fertilized oocytes and mean embryo scores were comparable between the two triggering agents. While implantation (36.53% vs, 32.93%), pregnancy (69.08% vs. 68.81%) and clinical pregnancy (41.3% vs. 40.2%) rates were comparable for the groups, the incidence of OHSS was significantly lower in GnRH than in hCG triggered cycles.

Conclusion(s): Fertilization, implantation and pregnancy rates from donor oocytes stimulated with GnRH antagonist protocol were identical for donor cycles triggered with hCG and GnRH agonist. GnRH antagonist triggering in egg donors was associated with lower rates of OHSS.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flowchart of the donors in the study
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/j.fertnstert.2004.12.053', 'is_inner': False, 'url': 'https://doi.org/10.1016/j.fertnstert.2004.12.053'}, {'type': 'PubMed', 'value': '16009163', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16009163/'}]}
    2. Shapiro BS, Daneshmand ST, Garner FC, Aquirre M, Ross R, Morris S. Effects of the ovulatory serum concentration of human chorionic gonadotropin on the incidence of ovarian hyperstimulation syndrome and success rates for in vitro fertilization. Fertil Steril. 2005;84:93–8. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1093/humrep/15.9.1965', 'is_inner': False, 'url': 'https://doi.org/10.1093/humrep/15.9.1965'}, {'type': 'PubMed', 'value': '10966996', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10966996/'}]}
    2. Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod. 2000;15:1965–8. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/j.fertnstert.2007.06.030', 'is_inner': False, 'url': 'https://doi.org/10.1016/j.fertnstert.2007.06.030'}, {'type': 'PubMed', 'value': '17981269', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/17981269/'}]}
    2. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Thomas S. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. Fertil Steril. 2008;90:231–3. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1093/humupd/dmi045', 'is_inner': False, 'url': 'https://doi.org/10.1093/humupd/dmi045'}, {'type': 'PubMed', 'value': '16254001', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16254001/'}]}
    2. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2006;12:159–68. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '16895632', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16895632/'}]}
    2. Orvieto R, Rabinson J, Meltzer S, Zohav E, Anteby E, Homburg R. Substituting HCG with GnRH agonist to trigger final follicular maturation—a retrospective comparison of three different ovarian stimulation protocols. Reprod Biomed Online. 2006;13:198–201. - PubMed

Publication types

Substances